UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

Journal of clinical oncology, 2011-05, Vol.29 (15), p.2121-2127

2011

Volltextzugriff (PDF)

A multicenter evaluation of treatment patterns and outcomes for Adamantinoma-like Ewing sarcoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e23500-e23500

2022

Volltextzugriff (PDF)

Efficacy of liposomal doxorubicin in patients with intra- and extra-abdominal desmoid fibromatosis

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.11581-11581

2022

Volltextzugriff (PDF)

A pilot study of the feasibility and utility of a fitness tracker to correlate activity level with patient reported outcomes (PROs) in sarcoma patients undergoing systemic therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.11559-11559

2021

Volltextzugriff (PDF)

Evaluation of formulation-associated ifosfamide neurotoxicity

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e23562-e23562

2022

Volltextzugriff (PDF)

A prospective study evaluating the association of patient-reported outcomes with activity level and sleep patterns in sarcoma survivors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.12085-12085

2023

Volltextzugriff (PDF)

Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.11028-11028

2019

Volltextzugriff (PDF)

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.11505-11505

2021

Volltextzugriff (PDF)

Reply to M.C. Garassino et al

Journal of clinical oncology, 2011-10, Vol.29 (28), p.3837-3837

2011

Volltextzugriff (PDF)

Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3031-3031

2018

Volltextzugriff (PDF)

A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1 + soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.11011-11011

2019

Volltextzugriff (PDF)

Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAF V600 mutation

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.9074-9074

2017

Volltextzugriff (PDF)

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer

Journal of thoracic oncology, 2014-04, Vol.9 (4), p.559-562

2014

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.11505-11505

2018

Volltextzugriff (PDF)

First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2508-2508

2017

Volltextzugriff (PDF)

Vemurafenib in patients with BRAF V600 mutant glioma: A cohort of the histology-independent VE-basket study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2004-2004

2017

Volltextzugriff (PDF)

Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.11048-11048

2017

Volltextzugriff (PDF)

A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7568-7568

2012

Volltextzugriff (PDF)

Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.11089-11089

2014

Volltextzugriff (PDF)

Patient-reported outcome instruments meaningful and relevant for tenosynovial giant cell tumor (TGCT): A qualitative study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.10521-10521

2015

Volltextzugriff (PDF)

A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7094-7094

2012

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(20)
Journal Of Thoracic Oncology
(1)

Menü

Weitere Dienste

Einstellungen

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

A multicenter evaluation of treatment patterns and outcomes for Adamantinoma-like Ewing sarcoma

Efficacy of liposomal doxorubicin in patients with intra- and extra-abdominal desmoid fibromatosis

A pilot study of the feasibility and utility of a fitness tracker to correlate activity level with patient reported outcomes (PROs) in sarcoma patients undergoing systemic therapy

Evaluation of formulation-associated ifosfamide neurotoxicity

A prospective study evaluating the association of patient-reported outcomes with activity level and sleep patterns in sarcoma survivors

Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS)

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma

Reply to M.C. Garassino et al

Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors

A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1 + soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival

Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAF V600 mutation

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer

A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study

First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study

Vemurafenib in patients with BRAF V600 mutant glioma: A cohort of the histology-independent VE-basket study

Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs)

A phase II study of erlotinib followed by chemotherapy on progression in an unselected population of advanced non-small cell lung cancer (NSCLC) patients

Enabling a genetically informed approach to cancer medicine: A retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel

Patient-reported outcome instruments meaningful and relevant for tenosynovial giant cell tumor (TGCT): A qualitative study

A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)

Suchergebnisse filtern